A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Completed · Phase 1

Conditions studied: Non-Small-Cell Lung Carcinoma

In brief

The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.

Key facts

Study ID

NCT00162318

Run by

Eli Lilly and Company

People needed

30

Starts

2005-03-01

Expected to finish

2006-04-01

Last updated by the study team

2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with advanced or metastatic non small cell lung cancer.
• Subjects should have had at least one prior chemotherapy with a platinum based therapy.

You may not qualify if…

• Subjects are excluded from this study if they do not have non small cell lung cancer that is advanced or metastatic or have not had at least one prior platinum based chemotherapy.

Where it is running

• Local Institution — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.